Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Other hematologic neoplasm 1Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Preleukemia 1Precancerous Conditions 1Neoplasms by Histologic Type 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Diseases 1Bone Marrow Diseases 1

Interventions

ponatinib 4pembrolizumab 3Rituximab 3Gemcitabine 3Cyclophosphamide 3130-nm albumin-bound paclitaxel 3pralsetinib 2napabucasin 2Vincristine 2Prednisone 2Irinotecan 2Imatinib Mesylate 2Etoposide 2Doxorubicin 2Carboplatin 2Brentuximab Vedotin 2tetulomab tetraxetan lu-177 1ruxolitinib 1ricolinostat 1pomalidomide 1pamiparib 1nirogacestat 1nilotinib 1ibritumomab tiuxetan 1denileukin diftitox 1bosutinib 1blinatumomab 1Vorinostat 1Temozolomide 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms by Histologic Type × CPI-0610 × Clear all
NCT02158858 2026-06-04

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Constellation Pharmaceuticals

Phase 1/2 Completed
336 enrolled 61 charts
MyeloidOther hematologic neoplasmOther neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡